Cargando…
Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial
Background: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is associated with frequent toxicities leading to dos...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777156/ https://www.ncbi.nlm.nih.gov/pubmed/36553163 http://dx.doi.org/10.3390/diagnostics12123154 |
_version_ | 1784856034548908032 |
---|---|
author | Dotinga, Maaike Vriens, Dennis van Velden, Floris H. P. Stam, Mette K. Heemskerk, Jan W. T. Dibbets-Schneider, Petra Pool, Martin Rietbergen, Daphne D. D. de Geus-Oei, Lioe-Fee Kapiteijn, Ellen |
author_facet | Dotinga, Maaike Vriens, Dennis van Velden, Floris H. P. Stam, Mette K. Heemskerk, Jan W. T. Dibbets-Schneider, Petra Pool, Martin Rietbergen, Daphne D. D. de Geus-Oei, Lioe-Fee Kapiteijn, Ellen |
author_sort | Dotinga, Maaike |
collection | PubMed |
description | Background: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is associated with frequent toxicities leading to dose reductions and withdrawal. A potential new treatment approach is to use TKIs as redifferentiation agent to restore RAI uptake to an extent that I-131 therapy is warranted. Prior studies show that short-term treatment with other TKIs restores RAI uptake in 50–60% of radioiodine-refractory DTC patients, but this concept has not been investigated for lenvatinib. Furthermore, the optimal duration of treatment with TKIs for maximal redifferentiation has not been explored. Methods and Design: A total of 12 patients with RAI-refractory DTC with an indication for lenvatinib will undergo I-124 PET/CT to quantify RAI uptake. This process is repeated after 6 and 12 weeks post-initiating lenvatinib after which the prospective dose estimate to target lesions and organs at risk will be determined. Patients will subsequently stop lenvatinib and undergo I-131 treatment if it is deemed effective and safe by predefined norms. The I-124 PET/CT measurements after 6 and 12 weeks of the first six patients are compared and the optimal timepoint will be determined for the remaining patients. In all I-131 treated patients post-therapy SPECT/CT dosimetry verification will be performed. During follow-up, clinical response will be evaluated using serum thyroglobulin levels and F-18 FDG PET/CT imaging for 6 months. It is hypothesized that at least 40% of patients will show meaningful renewed RAI uptake after short-term lenvatinib treatment. Discussion: Shorter treatment duration of lenvatinib treatment is preferred because of frequent toxicity-related dose reductions and drug withdrawals in long-term lenvatinib treatment. Short-term treatment with lenvatinib with subsequent I-131 therapy poses a potential new management approach for these patients. Since treatment duration is reduced and I-131 therapy is more tolerable for most patients, this potentially leads to less toxicity and higher quality of life. Identifying RAI-refractory DTC patients who redifferentiate after lenvatinib therapy is therefore crucial. Trial Registration: ClinicalTrials.gov, NTC04858867. |
format | Online Article Text |
id | pubmed-9777156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97771562022-12-23 Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial Dotinga, Maaike Vriens, Dennis van Velden, Floris H. P. Stam, Mette K. Heemskerk, Jan W. T. Dibbets-Schneider, Petra Pool, Martin Rietbergen, Daphne D. D. de Geus-Oei, Lioe-Fee Kapiteijn, Ellen Diagnostics (Basel) Protocol Background: Management of patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a challenge as I-131 therapy is deemed ineffective while standard-of-care systemic therapy with tyrosine kinase inhibitor (TKI) lenvatinib is associated with frequent toxicities leading to dose reductions and withdrawal. A potential new treatment approach is to use TKIs as redifferentiation agent to restore RAI uptake to an extent that I-131 therapy is warranted. Prior studies show that short-term treatment with other TKIs restores RAI uptake in 50–60% of radioiodine-refractory DTC patients, but this concept has not been investigated for lenvatinib. Furthermore, the optimal duration of treatment with TKIs for maximal redifferentiation has not been explored. Methods and Design: A total of 12 patients with RAI-refractory DTC with an indication for lenvatinib will undergo I-124 PET/CT to quantify RAI uptake. This process is repeated after 6 and 12 weeks post-initiating lenvatinib after which the prospective dose estimate to target lesions and organs at risk will be determined. Patients will subsequently stop lenvatinib and undergo I-131 treatment if it is deemed effective and safe by predefined norms. The I-124 PET/CT measurements after 6 and 12 weeks of the first six patients are compared and the optimal timepoint will be determined for the remaining patients. In all I-131 treated patients post-therapy SPECT/CT dosimetry verification will be performed. During follow-up, clinical response will be evaluated using serum thyroglobulin levels and F-18 FDG PET/CT imaging for 6 months. It is hypothesized that at least 40% of patients will show meaningful renewed RAI uptake after short-term lenvatinib treatment. Discussion: Shorter treatment duration of lenvatinib treatment is preferred because of frequent toxicity-related dose reductions and drug withdrawals in long-term lenvatinib treatment. Short-term treatment with lenvatinib with subsequent I-131 therapy poses a potential new management approach for these patients. Since treatment duration is reduced and I-131 therapy is more tolerable for most patients, this potentially leads to less toxicity and higher quality of life. Identifying RAI-refractory DTC patients who redifferentiate after lenvatinib therapy is therefore crucial. Trial Registration: ClinicalTrials.gov, NTC04858867. MDPI 2022-12-14 /pmc/articles/PMC9777156/ /pubmed/36553163 http://dx.doi.org/10.3390/diagnostics12123154 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Protocol Dotinga, Maaike Vriens, Dennis van Velden, Floris H. P. Stam, Mette K. Heemskerk, Jan W. T. Dibbets-Schneider, Petra Pool, Martin Rietbergen, Daphne D. D. de Geus-Oei, Lioe-Fee Kapiteijn, Ellen Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial |
title | Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial |
title_full | Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial |
title_fullStr | Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial |
title_full_unstemmed | Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial |
title_short | Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial |
title_sort | reinducing radioiodine-sensitivity in radioiodine-refractory thyroid cancer using lenvatinib (reset): study protocol for a single-center, open label phase ii trial |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777156/ https://www.ncbi.nlm.nih.gov/pubmed/36553163 http://dx.doi.org/10.3390/diagnostics12123154 |
work_keys_str_mv | AT dotingamaaike reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT vriensdennis reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT vanveldenflorishp reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT stammettek reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT heemskerkjanwt reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT dibbetsschneiderpetra reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT poolmartin reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT rietbergendaphnedd reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT degeusoeilioefee reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial AT kapiteijnellen reinducingradioiodinesensitivityinradioiodinerefractorythyroidcancerusinglenvatinibresetstudyprotocolforasinglecenteropenlabelphaseiitrial |